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Abstract 
Dilated Cardiomyopathy is an uncommon disease in children but morbidity 
and mortality in affected patients are high. This review discuses clinical 
presentation, diagnosis, medical management and prognosis of the condition, 
with an emphasis on recent advances that have influenced management of 
these children. 
MeSH: Cardiomyopathy, congestive, Myocarditis/diagnosis, Heart 
transplantation, Prognosis 
 
Presentation and investigation of dilated 
cardiomyopathy 
At the time of presentation the child with dilated cardiomyopathy (DCM) is 
usually in symptomatic cardiac failure, and at initial assessment, it is important 
to differenciate this condition from bronchiolitis. The chest x-ray features of 
increased cardiothoracic ratio, with evidence of lateral bronchial displacement 
due to left atrial enlargement and pulmonary plethora in association with 
hepatomegaly, raises clinical suspicion of the diagnosis (figure 1). 
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Figure 1 Chest x-ray in a child with dilated cardiomyopathy 
 
 
 
Echocardiography is confirmatory showing dilatation of cardiac chambers, 
with or without mitral regurgitation (figure 2), and reduced ventricular function 
on M Mode analysis. It is very important to exclude mural thrombus on 
echocardiogram as its presence requires urgent treatment. 
 
Figure 2 On left: echocardiographic apical four chamber view of dilated 
cardiomyopathy - note mitral regurgitation. Middle: parasternal long axis view 
of dilated cardiomyopathy. Right: note mitral regurgitation in same view. 
 
 
Both coronary arteries should be identified in an attempt to exclude 
anomalous origin of the left coronary artery form the pulmonary artery 
although this can be difficult1 and angiography may be required (figure 3). 
The electrocardiogram may be more useful in this respect showing deep Q 
waves in lead I and wide Q waves in lead AVL, where the origin of the left 
coronary artery is anomalous.2 
More commonly in idiopathic DCM sinus tachycardia, increased left 
ventricular voltages and ischaemic changes are seen on ECG at presentation. 
The QRS complex may be broad due to conduction disturbance and evidence 
of right atrial hypertrophy and left atrial hypertrophy is sometimes evident. 24 
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hour ECG monitoring will exclude chronic tachycardia with secondary 
ventricular dilatation e.g. permanent junctional reciprocal tachycardia, which is 
associated with a moderate increased heart rate and an abnormal P axis and 
will also identify children with secondary arrhythmias. 
 
Figure 3 Aortogram in anomalous origin of left coronary artery 
 
Differential diagnosis 
There are a number of alternate diagnoses that need to be excluded at the 
time of presentation, as management and therapeutic strategies may need to 
be altered accordingly. Anomalous origin of the left coronary artery, the ECG 
features of which are described above, usually presents at 2-3 months and 
can be confirmed at cardiac catheter. This condition is surgically correctable. 
Myocarditis is more difficult to diagnose with accuracy but an attempt should 
be made as spontaneous resolution is likely and short-term mechanical 
support may be more appropriate than referral for transplantation. Positive 
viral cultures or increased antibody titres on paired serum samples may help. 
Common causes include viral infection with coxachie, echo, HIV, measles, 
mumps and rubella but all families of micro-organisms have been implicated. 
Myocardial biopsy is rarely indicated, because of the risk. 
In most children dilated cardiomyopathy is a sporadic condition of unknown 
cause. However familial cases have been reported with autosomal dominant 
with incomplete penetrance, recessive and x-linked inheritance patterns 
described. Michels et al3 demonstrated a prevalence of familial disease in 
20% of index cases in a prospective study where asymptomatic first-degree 
relatives were screened. No features specific to familial disease have been 
identified. It is our policy to offer such screening, and this needs to be handled 
sensitively. 
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DCM as a secondary disease 
DCM is rarely due to systemic disease however as myocardial damage may 
be reversible with treatment of the underlying pathology it is essential to 
attempt to rule out metabolic, endocrine, storage, mitochondrial and 
connective tissue disorders at first presentation. Blood may be taken for 
lactate, glucose, amino acids, carnitine and acylcarnitine, cholesterol and 
triglycerides, thyroid function, creatinine kinase, iron and iron binding capacity 
and uric acid. A full blood count to assess absolute neutrophil count and 
vacuolated lymphocytes may also be helpful. Early morning urine analysis for 
amino-acids, organic acids and glycosamine glycans may further exclude 
metabolic disease. 
 
Medical management 
The objective of drug therapy in DCM is to give supportive relief and maximize 
cardiac function. There is not as yet a treatment that offers a cure. 
Diuretic have an established role particularly in their ability to produce rapid 
symptom relief, but earlier use of ACE inhibitors has probably resulted in 
lower doses being used in recent years. ACE inhibitors have been 
consistently shown to reduce morbidity and mortality in adult studies,4,5 
Enalapril maleate was used in these series, there is limited information 
available on its use in children where captopril is most commonly prescribed. 
ACE inhibitors are generally well tolerated, their principle side effects include 
first dose hypotension, non-productive cough, and a risk of hyperkalaemia, 
especially in patients already on potassium supplements or potassium sparing 
diuretics. 
Treatment with B-blockers needs also to be considered. The increased 
sympathetic drive that occurs as a compensatory mechanism in chronic heart 
failure appears to have an inverse relationship with prognosis6,7. B-blockers 
down regulate this sympathetic overdrive8 and the evidence that they improve 
outcome in adult patients with chronic heart failure is increasing9,10,11. The a-
adrenergic effects of the third generation B-blockers e.g. Carvedilol and 
Timolol also cause vasodilatation and this may be helpful. 
Digoxin has a place as an orally active inotrope, but its failure to actively 
reduce mortality in adults12 means it is increasingly relegated to second line 
therapy. Intravenous inotropes may occasionally be necessary to support the 
child in end stage cardiac failure. Their use is an indication for transplant 
assessment in some centers.13 
Arrhythmias may also require treatment but this needs to be carefully 
evaluated, as many anti-arrhythmic drugs are negatively inotropic. All children 
with poor LV function are at risk of mural thrombus and should be treated 
prophylactically with aspirin, the detection of clot requires urgent 
anticoagulation (fig. 4). 
Growth hormone may be effective as add on therapy in the child who is failing 
to improve on conventional medical management. Early studies in adults14 
have shown improvement in LV function and exercise tolerance and reduced 
myocardial oxygen consumption with GH therapy that deteriorated when 
therapy was discontinued. In the future subcutaneous GH could have a role 
as a medical ‘bridge to transplantation’ but further work need to be done. 
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Figure 4 Mural thrombus (MT) in a child with dilated cardiomyopathy 
 
 
Prognosis 
Mortality for DCM is highest in the first year after diagnosis with a reported 
survival at 1 and 5 years after first presentation of 79% and 61% 
respectively.15 Early deaths are principally caused by severe heart failure. 
Some late deaths are sudden, presumably due to arrhythmia, in children who 
fail to recover to normal ventricular function. While it is accepted that the risk 
of mortality is high there is less agreement as to predictors of poor outcome. 
Failure of improvement or deterioration in shortening fraction, ventricular 
arrhythmias, detection of mural thrombus, presentation at age >2years, 
endocardial fibroelastosis and left ventricular end diastolic pressure > 
20mmHg have all been put forward as adverse prognostic factors.15,16,17,18 
 
Mechanical and surgical support 
Left ventricular assist devices and biventricular assist devices, although not 
widely available yet in the UK will have a role in the short term, providing a 
bridge to transplant for the child with intractable cardiac failure. In the future 
indwelling axial flow impeller pumps such as the JARVIK2000 Heart may have 
a place in the long term mechanical support of this difficult group of patients 
(fig. 5).19 
End stage cardiac failure secondary to DCM has been the most common 
indication for heart transplantation in children and adolescents.20 Survival 
statistics post transplantation are improving. In a series reported from Great 
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Ormond Street, Adwani reported survival for 95% at 1 year and 87% at 3 
years, in patients transplanted for dilated cardiomyopathy.13 Currently the 
principle limiting factor in paediatric cardiac transplantation is a shortage of 
donor organs hence the importance of developing a mechanical support 
system suitable for use in the long term. 
A second surgical option is the Batista operation where a partial left 
ventriculectomy is combined with mitral valve repair to restore left ventricular 
dimensions to normal thus improving pump function. Paediatric experience of 
this operation is limited but a 55% 2 year survival was reported in adult 
patients in the US, with most survivors showing symptomatic improvement.21 
 
Figure 5 Axial flow impeller pump 
 
 
Conclusion 
Management of children with dilated cardiomyopathy remains difficult but 
recent advances including early introduction of ACE inhibitors and B-blockers 
may improve what is currently a bleak outlook. In the future implantable left 
ventricular assist devices may provide interim mechanical support, but referral 
for transplantation remains the cornerstone of treatment. 
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